Creative Medical Technology announced a major stride in combating Type 1 Diabetes Mellitus, or T1D. The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CELZ:
- Creative Medical Technology gets orphan drug designation from FDA for CELZ-101
- Creative Medical Technology’s CELZ-101 granted FDA orphan designation
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue